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Methoxyacetic acid (MAA) is the primary 
metabolite of the industrial solvent ethylene 
glycol monomethyl ether (EGME), which 
has been used in a variety of coatings and as 
a jet fuel additive (Gargas et al. 2000; Miller 
et al. 1983). Interest in EGME and MAA 
stems from epidemiologic analyses and labo­
ratory studies that have linked exposure to 
these compounds with reproductive toxicity. 
In women, occupational exposure to ethylene 
glycol ethers has been associated with increased 
risks of spontaneous abortion and subfertility 
(Correa et al. 1996), whereas exposed males 
have decreased sperm counts (Welch et al. 
1988). In laboratory studies, EGME has been 
shown to target the ovarian luteal cell, sup­
press cyclicity, and inhibit ovulation in female 
rats (Davis et al. 1997); in male rats, EGME 
has been reported to reduce testicular size and 
fertility (Rao 1971). Subsequent studies have 
shown that many of the untoward reproduc­
tive effects observed after EGME exposure 
can be reproduced by exposure to MAA alone, 
suggesting that MAA is primarily responsible 
for the compromised reproductive function 
associated with EGME exposure (Davis et al. 
1997; Foster et al. 1984). 
The chemical structure of MAA places 
it in the short­chain fatty acid family, which 
includes the anti  epileptic drug valproic acid 
(VPA) and the intestinal bacterial product 
sodium butyrate (NaB). Interestingly, VPA 
is also associated with reproductive toxicity, 
including menstrual abnormalities and poly­
cystic ovaries (Isojarvi et al. 1993; Lofgren et al. 
2007; O’Donovan et al. 2002), suggesting 
the short­chain fatty acids may share similar 
mechanisms of action that lead to reproductive 
toxicity. A common feature of MAA, VPA, 
and NaB is their ability to inhibit histone 
deacetylases (Boffa et al. 1978; Gottlicher et al. 
2001; Jansen et al. 2004; Phiel et al. 2001; 
Sealy and Chalkley 1978), which suggests that 
one of their major mecha  nisms of action may 
be to alter gene expression via histone hyper­
acetylation. Microarray analyses have con­
firmed that MAA and VPA, as well as other 
histone deacetylase (HDAC) inhibitors, alter 
gene expression profiles in human cell lines; 
however, the total number of genes regulated 
by these compounds is relatively low (Jansen 
et al. 2004; Reid et al. 2005). In addition to 
altering gene expression profiles through his­
tone hyper  acetylation, several HDAC inhibi­
tors, as well as MAA and other short­chain 
fatty acids, have been shown through in vitro 
analyses to modulate intra  cellular signal­
ing pathways such as the MAPK (mitogen­ 
activated protein kinase) pathway, which may 
contribute to their effects on gene expression 
and cell viability (Jansen et al. 2004; Jung 
et al. 2005; Michaelis et al. 2006; Rivero and 
Adunyah 1996; Witt et al. 2002). 
Although the histone deacetylase inhibitory 
activity of MAA has been characterized, little 
is known regarding the effects of this com­
pound on estrogen signaling, which is critical 
to reproductive function in both the male and 
female (Hewitt et al. 2005). Estrogens use both 
genomic and non  genomic mechanisms to alter 
the gene expression patterns and proliferative 
rates of target tissues and cells (Bjornstrom 
and Sjoberg 2005). Many of these effects are 
mediated by estrogen receptors ERα and ERβ, 
which are differentially expressed transcription 
factors that bind estrogens and transcription­
ally regulate the expression of numerous genes. 
In light of the role of estrogen signaling in nor­
mal reproductive function and gene expression 
and the reproductive toxicity associated with 
MAA, we sought to determine what effects 
MAA might have on estrogen signaling in vitro 
and in vivo to gain further insight into the 
molecular mecha  nisms of action of MAA.
Materials and Methods
Mammalian cell culture. MCF­7 cells 
(ATCC, Manassas, VA, USA) were cultured 
in Dulbecco’s modified Eagle medium: 
Nutrient Mixture F­12 (DMEM/F­12; 
Invitrogen Corporation, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum 
(FBS; Atlanta Biologicals, Lawrenceville, GA, 
USA), penicillin (100 U/mL), and strepto­
mycin (100 µg/mL) and incubated at 37°C 
in a humidified atmosphere containing 5% 
CO2. HeLa cells (ATCC) were cultured in 
DMEM (Invitrogen) supplemented with 
10% FBS, penicillin (100 U/mL), and 
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streptomycin (100 µg/mL) and incubated at 
37°C in a humidified atmosphere containing 
5% CO2.
Animals and treatments. All procedures 
involving animals were approved by the 
Animal Care and Use Committee of the 
National Institute of Environmental Health 
Sciences. All animals were treated humanely 
and with regard for alleviation of suffering. 
Ten­week­old ovariectomized C57BL/6 
mice (Charles River Laboratories, Raleigh, 
NC, USA) were housed in plastic cages in 
a temperature­controlled room (21–22°C) 
with a 12­hr light/dark cycle. Mice were 
given NIH 31 mouse chow (Ziegler Bros. 
Inc., Gardner, PA) and fresh water ad libitum. 
Groups of mice (n = 3/group) were treated by 
intra  peritoneal injection with saline, 1 µg/kg 
17β­estradiol (E2), or 400 mg/kg MAA for 
2 hr before necropsy. One additional group 
was treated with 400 mg/kg MAA 30 min 
before treatment with 1 µg/kg E2 for 2 hr. 
Animals were killed using CO2, and uteri 
were collected and snap­frozen. 
RNA isolation and real-time PCR analys  is. 
Cells. MCF­7 cells were plated into 6­well 
plates (1 × 106 cells/well) and incubated over­
night in DMEM/F­12 medium supplemented 
with 10% FBS. The next day, the media was 
aspirated from each well, cells were washed 
with phosphate­buffered saline (PBS), and 
fresh media [DMEM/F­12 containing 10% 
charcoal/dextran­treated FBS (HyClone, 
Logan, UT, USA)] was added to each well. The 
cells were incubated overnight and then treated 
for 24 hr. At the end of the treatment period, 
the cells were harvested and total RNA was 
isolated using the RNeasy Mini Kit (Qiagen 
Incorporated, Valencia, CA, USA) according 
to the manufacturer’s protocol. 
Uterine tissue. Frozen uterine tissue was 
pulverized, and total RNA was isolated using 
TRIzol reagent (Invitrogen) according to the 
manufacturer’s protocol.
Real-time reverse-transcriptase polym-
erase chain reaction (RT-PCR). Synthesis 
of complementary DNA (cDNA) and analy­
sis of gene­specific cDNA concentrations by 
real­time PCR were performed as previously 
described (Deroo et al. 2004). Primers for real­
time PCR were designed with Primer Express 
software, version 2.0 (Applied Biosystems 
Incorporated, Foster City, CA, USA). 
Western blots. MCF­7 cells were cultured 
and treated as described above. After treat­
ment, cells were washed with PBS and lysed 
with M­PER Mammalian Protein Extraction 
Reagent (Thermo Fisher Scientific, Rockford, 
IL, USA) containing Halt Protease Inhibitor 
Cocktail (Thermo Fisher Scientific) accord­
ing to the manufacturer’s protocol to obtain 
total protein. Protein concentrations were 
determined using the BCA Protein Assay Kit 
(Thermo Fisher Scientific), and equal amounts 
of protein (20 µg) were separated on NuPAGE 
Novex 10% Bis­Tris gels (Invitrogen). Proteins 
were transferred to nitro  cellulose membranes 
and stained using the MemCode Reversible 
Protein Staining Kit (Thermo Fisher Scientific) 
to ensure equal protein transfer. Membranes 
were blocked and incubated with antibodies 
in Tris­buffered saline containing 5% milk 
and 0.1% Tween­20. ERα protein levels were 
evaluated with a rabbit polyclonal antibody 
(sc­7207; Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) and a horse  radish peroxidase­
conjugated anti­rabbit antibody (NA934V; 
Amersham/GE Healthcare Bio­Sciences 
Corporation, Piscataway, NJ, USA). ERα 
protein levels were visualized with ECL Plus 
(Amersham/GE Healthcare Bio­Sciences) and 
BIOMAX MR film (Kodak/Sigma­Aldrich 
Corporation, St. Louis, MO, USA). 
Transfections. HeLa cells were plated at 
a density of 1 × 105 cells/well into 24­well 
plates in standard growth medium overnight. 
The following day the medium was changed 
to DMEM supplemented with 1% charcoal­
dextran stripped FBS (SFBS; Hyclone) and 
transfected using Fugene 6 (Roche Applied 
Science, Indianapolis, IN, USA) reagent 
according to the manufacturer’s protocol. 
After transfection, the cells were incubated 
overnight in media supplemented with 10% 
SFBS. The cells were then treated for 24 hr 
and harvested and assayed for luciferase and 
β­galactosidase activities using the Luciferase 
Assay System (Promega Corporation, 
Madison, WI, USA) and the β­Galactosidase 
Enzyme Assay System (Promega). 
Statistical analysis. Data were analyzed for 
statistical significance using the Mann­Whitney 
non  parametric test.
Results
MAA potentiates exogenous ER-mediated   
signaling. The reproductive toxicities associ­
ated with MAA exposure in both humans and 
animals are similar to some of the reproduc­
tive phenotypes observed in both ERα knock­
out mice (αERKO) and aromatase knockout 
mice (ArKO), which suggests that MAA may 
impart its untoward reproductive effects by 
compromising estrogen­mediated signaling. 
Interestingly, despite the parallel phenotypes of 
MAA exposure and animal models of compro­
mised estrogen signaling, MAA has been shown 
to enhance exogenous nuclear receptor signal­
ing, including ER signaling (Jansen et al. 2004). 
Because these in vitro data are incongru­
ent with the reproductive toxicity associated 
with MAA, we performed similar in vitro 
experiments to assess the effects of MAA on 
estrogen signaling. We transiently transfected 
ER­negative HeLa cells with an expression 
vector for human ERα or ERβ along with an 
estrogen­inducible 3X­ERE­TATA­Luc firefly 
luciferase reporter plasmid and a constitutively 
active cytomegalovirus (CMV)­β­galactosidase 
reporter plasmid and treated the cells for 24 hr 
with a solvent control or increasing concen­
trations of E2 in the absence and presence of 
5 mM MAA. Consistent with prior observa­
tions, our luciferase assay data show that 
MAA potentiates the activity of E2 in HeLa 
cells transfected with the estrogen­responsive 
luciferase reporter and either human ERα or 
ERβ (Figure 1A,B). The ER expression vec­
tor is necessary for this response, as identically 
treated HeLa cells transfected with the reporter 
in the absence of ERα and ERβ possessed mini­
mal luciferase activity that was unaltered by 
treatment with E2 alone or E2 plus MAA (data 
not shown). In contrast, when ER­positive 
MCF­7 cells were transfected with only the 
3X­ERE­TATA­Luc and CMV­β­galactosidase 
reporter plasmids and treated identically to 
the HeLa cells, no potentiation of E2­induced 
luciferase activity was observed with MAA 
cotreatment (Figure 1C). However, MAA was 
able to potentiate estrogen­stimulated luciferase 
activity in MCF­7 cells cotransfected with an 
expression vector for human ERα (Figure 1C). 
Interestingly, MAA alone increased luciferase 
activity relative to vehicle controls in HeLa 
cells transfected with either ERβ (~ 4.6­fold) 
or ERα (~ 3­fold) and in MCF­7 cells trans­
fected with ERα (~ 6.5­fold) (Figure 1A–1C). 
Because the MAA­mediated potentiation 
of E2­stimulated signaling in both cell lines 
was observed only after transfection with ER 
expression vectors and because MAA alone 
was able to increase luciferase activity relative 
to vehicle controls, we examined the effect of 
MAA on exogenous ERα expression in HeLa 
cells. MAA dose­dependently increased the 
expression of ERα protein in HeLa cells trans­
fected with the human ERα expression vec­
tor, which may account for the potentiation of 
estrogen­induced luciferase activity observed in 
the transfection experiments with exogenous 
ER (Figure 1D). We observed this effect in the 
presence and absence of 10 nM E2 (data not 
shown for E2). 
The expression vector for both ERα 
and ERβ is pcDNA3.1, which contains a 
CMV promoter. To determine if MAA was 
increasing ER expression by activating the 
CMV promoter within the expression vec­
tor, we transiently transfected HeLa cells 
with a renilla luciferase plasmid containing 
a CMV promoter (pRL­CMV) and treated 
the cells with increasing concentrations 
of MAA. We observed a concentration­ 
dependent increase in luciferase activity, 
with maximum activation (~ 30­fold relative 
to vehicle control) occurring after exposure 
to 20 mM MAA (Figure 1E). In the same 
experiments 5 mM MAA induced an ~ 8­fold 
increase in luciferase activity, indicating that 
this MAA concentration can significantly 
activate the CMV promoter. These data Henley et al.
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suggest that the MAA­mediated potentiation 
of E2­stimulated signaling in these transient 
transfection experiments is due to an increase 
in exogenous human ER expression via trans­
activation of the CMV promoter by MAA. 
Interestingly, MAA also trans  activated the 
pRL­tk and pRL­SV40 promoters in a dose­
dependent fashion, demon  strating 12­fold 
and 10­fold increases in luciferase activity, 
respectively, after exposure to 5 mM MAA 
(data not shown). 
MAA treatment reduces endogenous ERα 
expression. MAA­induced trans  activation of 
the CMV promoter complicates the interpre­
tation of data obtained from in vitro experi­
mental systems incorporating exogenous 
ER. Therefore, we performed experiments to 
examine the effect of MAA on the endogenous 
expression of ERα in MCF­7 cells. MCF­7 
cells were treated with increasing concentra­
tions of MAA, and endogenous ERα protein 
expression was detected by Western blot. We 
observed a concentration­dependent decrease 
in endogenous ERα protein expression, with 
maximal decreases occurring after treatment 
with 20 mM MAA, the highest concentra­
tion tested in these experiments (Figure 2A). 
To determine if the decrease in ERα protein 
levels corresponded with decreased steady­
state levels of ERα mRNA, MCF­7 cells were 
treated with 5 mM MAA for 24 hr, and ERα 
expression was analyzed by real­time PCR. 
Treatment with 5 mM MAA decreased the 
expression of ERα mRNA by ~ 50% relative 
to vehicle controls (Figure 2B), indicating that 
the decreased protein expression is due, at least 
in part, to diminished levels of ERα mRNA. 
Further experiments were performed in 
mice to determine if this effect was observed 
in vivo. Ovariectomized C57/BL6 mice 
were treated for 2.5 hr with either saline or 
400 mg/kg MAA, and uteri were collected 
for measure  ment of steady­state levels of ERα 
mRNA by real­time PCR. The dose of MAA 
used in these experiments was based on a pre­
vious report showing that this dose affects 
nuclear receptor signaling in the mouse uterus 
(Jansen et al. 2004). MAA decreased ERα 
expression in the mouse uterus by ~ 30% rela­
tive to controls at 2.5 hr (Figure 2C). Although 
this decrease was not statistically significant, the 
trend observed in these experiments indicates 
that MAA has similar effects on endogenous 
ERα expression in vitro and in vivo. 
MAA treatment disrupts estrogen-mediated 
gene expression. We performed further experi­
ments to determine if decreased ERα expres­
sion after MAA treatment resulted in disrupted 
ERα­mediated signaling. Toward this end, 
we treated MCF­7 cells with either 1 nM E2, 
5 mM MAA, or 1 nM E2 plus 5 mM MAA 
for 24 hr, and evaluated estrogen­regulated 
gene expression by real­time PCR. As shown 
in Figure 3A, the expression of pS2, MYC, 
GREB1, SPUVE, and MCM3 was potentiated 
by E2 treatment; however, pretreatment with 
5 mM MAA attenuated the estrogen­induced 
responses. Taken together, these data show that 
MAA attenuates endogenous ER signaling, 
resulting in disruption of estrogen­modulated 
endogenous gene expression in MCF­7 cells. 
To determine whether MAA has a similar 
effect on estrogen­modulated gene expression 
in vivo, ovariectomized mice were treated for 
2 hr with 1 µg/kg E2, 400 mg/kg MAA, or 
1 µg/kg E2 plus 400 mg/kg MAA, and uteri 
were collected for analysis of gene expression 
by real­time PCR. The MAA dose used in these 
experiments is based on a previously published 
report showing that this dose affects nuclear 
receptor signaling in the mouse uterus (Jansen 
et al. 2004). The mRNA levels of the estrogen­ 
inducible genes Greb1, Inhbb, and Fos were 
increased after treatment with E2 alone; 
however, a 30­min pretreatment with MAA 
reduced the E2­mediated stimulation of each 
Figure 1. Activation of the CMV promoter by MAA in vitro. (A) HeLa cells were transfected with a human 
ERβ expression vector, the estrogen­responsive 3X­ERE­TATA­Luc reporter plasmid, and the CMV­β­gal 
reporter plasmid, treated for 18 hr with vehicle, increasing concentrations of E2, 5 mM MAA, or increas­
ing concentrations of  E2 plus 5 mM MAA, and assayed for luciferase activity. Data represent the average 
fold over control (± SE) of duplicate samples from three independent experiments. (B) HeLa cells were 
transfected with a human ERα expression vector, 3X­ERE­TATA­Luc, and CMV­β­gal and treated identi­
cally to the cells in (A). Data represent the average fold over control (± SE) of duplicate samples from three 
independent experiments. (C) MCF­7 cells were transfected with the 3X­ERE­TATA­Luc reporter plasmid 
and the CMV­β­gal reporter plasmid with and without the human ERα expression vector. The cells were 
treated as described for (A). Data represent the average fold over control (± SE) of duplicate samples from 
three independent experiments. (D) HeLa cells were transfected with a human ERα expression vector and 
treated with either vehicle or increasing concentrations of MAA for 18 hr. ERα protein expression was 
analyzed by Western blot. Data are representative of three independent experiments. (E) HeLa cells were 
transfected with the pRL­CMV reporter plasmid, treated with either vehicle or increasing concentrations 
of MAA for 18 hr, and assayed for luciferase activity. Data represent the average fold over control (± SE) of 
duplicate samples from three independent experiments.
*p < 0.05 compared with E2 treatment. **p < 0.05, and #p < 0.01, compared with E2 treatment. ##p < 0.01 compared with 
vehicle control.
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Figure 2. Effect of MAA on endogenous ERα expression in vitro and in vivo. (A) MCF­7 cells were treated 
for 24 hr with either vehicle [ethanol (EtOH)] or increasing concentrations of MAA, and ERα protein 
expression was assessed by Western blot. Data are representative of results from three independent 
experiments. (B) MCF­7 cells were treated for 24 hr with either vehicle or 5 mM MAA, and ERα mRNA 
levels were meas  ured by real­time PCR. Data represent the average fold over control (± SE) obtained 
from duplicate samples in four independent experiments. (C) Uteri were collected from mice treated for 
2.5 hr with either saline or 400 mg/kg MAA, and real­time PCR was performed to determine the levels of 
ERα mRNA in each sample. Data are plotted as fold over control (± SE) and represent the average values 
obtained from three mice per treatment.
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gene (Figure 3B). Although statistical signifi­
cance was not reached in these experiments, 
the clear trend in MAA­mediated attenuation 
of E2­stimulated mouse uterine gene expres­
sion indicates that MAA has similar effects on 
in vitro and in vivo estrogen signaling. 
Discussion and Conclusions
EGME exposure is associated with reproduc­
tive toxicity in both humans and animals, 
and the majority of these effects are attributed 
to MAA, the primary metabolite of EGME. 
Despite an established role for estrogen signal­
ing in reproductive function, limited informa­
tion is available regarding the effects of MAA 
on estrogen action. Therefore, in the present 
study we examined the effects of MAA on 
estrogen signaling, as altered estrogen signal­
ing may be responsible for some of the repro­
ductive toxicity associated with MAA. Our 
results show that MAA exerts anti  estrogenic 
effects in vitro and in vivo by reducing 
endogenous ERα expression and attenuating 
E2­mediated gene expression. 
Members of the short­chain fatty acid fam­
ily such as MAA, VPA, and NaB elicit numer­
ous responses in cells and tissues. One such 
response that has been described for MAA is 
the inhibition of histone deacetylase activity 
(Jansen et al. 2004), which appears to be a 
common mecha  nism of action for the short­
chain fatty acids (Boffa et al. 1978; Gottlicher 
et al. 2001; Phiel et al. 2001; Sealy and 
Chalkley 1978). Because HDAC inhibitors 
exert a variety of effects on cells and tissues, 
including altered gene expression, cell cycle 
arrest, and apoptosis, many of the responses 
elicited by the short­chain fatty acids are likely 
associated with their histone deacetylase inhibi­
tory activity. Our results show that, in MCF­7 
cells, MAA alone was able to decrease the 
steady­state mRNA levels of ERα (1.9­fold 
decrease) and the estrogen­responsive genes 
pS2 (1.6­fold), MYC (1.5­fold), and SPUVE 
(2.7­fold) compared with vehicle controls 
(Figures 2B and 3A), whereas it increased the 
expression of CDKN1C (4.2­fold increase), a 
gene that was modestly down  ­regulated by E2 
in our experiments (data not shown). However, 
some genes measured in this study, includ­
ing GREB1 and MCM3, were not altered by 
treatment with MAA alone (Figure 3A). These 
results are consistent with those observed for 
other short­chain fatty acids and other HDAC 
inhibitors for which the expression levels of 
only a small number of genes are significantly 
altered. For example, treatment of MCF­7 cells 
with either VPA or trichostatin A (TSA) results 
in ~ 6% and ~ 20% changes, respectively, in 
the number of genes whose expression is altered 
greater than 2­fold as determined from micro­
array analyses (Reid et al. 2005). A comparison 
of the gene expression profiles after treatment 
of MCF­7 cells with MAA, VPA, NaB, sub­
eroylanilide hydroxamic acid (SAHA), or TSA 
shows that many of the same genes are simi­
larly affected by each compound, including 
ERα, pS2, SPUVE, and CDKN1C (Figures 2B 
and 3A) (Reid et al. 2005). This suggests that 
most of these alterations in gene expression are 
due to a common mechanism, which is likely 
inhibition of histone deacetylase activity.
Because ERα plays an obligatory role in 
many aspects of estrogen­mediated signaling, 
our observation that MAA reduces endoge­
nous ERα expression in vitro and in vivo sug­
gests that estrogen­mediated signaling may be 
compromised. Indeed, our in vitro and in vivo 
analyses confirm that MAA inhibits estrogen­
mediated effects on gene expression, show­
ing for the first time that MAA antagonizes 
E2­stimulated expression of ERα target genes. 
The short­chain fatty acids VPA and NaB have 
also been shown to reduce ERα expression 
in vitro (Reid et al. 2005; Stevens et al. 1984), 
suggesting that they may disrupt estrogen sig­
naling as well. Toward this end, VPA, in the 
absence of E2, has been shown to decrease 
the expression of ~ 90% of the genes that are 
up­regulated by E2 treatment in MCF­7 cells 
(Reid et al. 2005) and to reduce E2­stimulated 
MCF­7 cell proliferation (Olsen et al. 2004). 
In addition, NaB, in the absence of estrogen, 
has been reported to inhibit MCF­7 cell pro­
liferation (Abe and Kufe 1984). Furthermore, 
NaB attenuates E2­stimulated expression of 
the known estrogen target genes progesterone 
receptor and pS2 (De los Santos et al. 2007). 
Similar results have been observed for the 
HDAC inhibitors TSA and SAHA, suggesting 
that histone hyper  acetylation may be respon­
sible for the anti  estrogenic effects of the short­
chain fatty acids (De los Santos et al. 2007; 
Reid et al. 2005). Our in vivo data demon­
strate that MAA reduces ERα expression in the 
mouse uterus by ~ 30% compared with con­
trols (Figure 2C) and attenuates E2­stimulated 
gene expression in the uterus (Figure 3B). The 
modest decrease in ERα expression in these 
studies suggests that the changes observed in 
E2­stimulated gene expression may not be due 
solely to decreased ERα expression, but are 
likely due to additional mechanisms of action 
for MAA. This effect is not due to MAA acting 
as a competitive antagonist for ERα, as MAA 
does not compete with E2 for binding to ERα 
(Jansen et al. 2004). Taken together, these data 
suggest that the anti  estrogenic effects of the 
short­chain fatty acids are a class effect that 
may be due to their inherent HDAC inhibi­
tory activities, because MAA, VPA, and NaB 
have all been shown to reduce endogenous 
ERα expression and have been characterized as 
HDAC inhibitors. 
Although MAA imparts anti  estrogenic 
effects on endogenous ER signaling, it 
enhances estrogen­stimulated reporter activity 
in the presence of exogenous ERα and ERβ 
in both HeLa and MCF­7 cells. Similar results 
have been reported for MAA with respect to 
the exogenous ER as well as other exogenous 
nuclear receptors (Bagchi et al. 2009; Jansen 
et al. 2004). We observed these enhanced 
responses in MCF­7 cells only when cells 
were cotransfected with ER expression vec­
tors, indicating that the presence of the ER 
expression vector is necessary for this effect. 
In contrast to endogenous ERα expression, 
which is decreased after MAA exposure, exog­
enous ERα expression is increased after MAA 
treatment in the presence and absence of E2, 
and this increase correlates with enhanced 
luciferase activity in our reporter assays. The 
under  lying mechanism of MAA­induced 
increases in exogenous ER expression is activa­
tion of the CMV promoter, which is present 
in the ER expression vectors used in this study 
Figure 3. Effect of MAA on estrogen­mediated endogenous gene expression in vitro and in vivo. (A) MCF­7 cells were pretreated with either vehicle [ethanol 
(EtOH)] or 5 mM MAA for 2 hr and then treated for 18 hr with either vehicle or 1 nM E2. The expression of endogenous estrogen­responsive genes was analyzed 
by real­time PCR. Data represent the average fold over control (± SE) of duplicate samples from at least three independent experiments. (B) Mice were pretreated 
for 30 min with either saline or 400 mg/kg MAA and then treated with either vehicle or 1 µg/kg E2 for 2 hr. Uteri were collected and estrogen­responsive gene 
expression was analyzed by real­time PCR. Data represent the average fold over control (± SE) obtained from three mice per treatment.
#p < 0.01 compared with 1 nM E2 alone.
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and is frequently used in other expression vec­
tors. The short­chain fatty acids VPA and NaB 
and the HDAC inhibitor TSA have also been 
shown to activate the CMV promoter (Dion 
et al. 1997; Phiel et al. 2001), which sug­
gests that this is another shared feature of the 
short­chain fatty acid family and some HDAC 
inhibitors. The disparate results obtained in 
our experiments comparing the effects of MAA 
on endogenous and exogenous ER signaling 
highlight the importance of our observation 
that MAA activates the CMV promoter, as 
each set of results would lead to opposite con­
clusions regarding the effect of MAA on ER 
signaling. Based on this observation, careful 
considera  tion should be given to experimental 
design when examining the effects of MAA 
and other short­chain fatty acids on nuclear 
receptor signaling to avoid errant conclusions 
based on experimental artifacts associated with 
CMV­containing expression vectors. This 
observation extends to expression vectors con­
taining either TK or SV40 promoters, which 
were also potently transactivated by MAA in 
our experiments (data not shown). Similar 
data have been reported for VPA and NaB 
with respect to the SV40 promoter, again sug­
gesting a class effect for the short­chain fatty 
acids (Chen et al. 1999; Gorman et al. 1983). 
We have demonstrated that MAA reduces 
endogenous ERα expression and that MAA 
treatment inhibits estrogen­mediated endog­
enous gene expression in vitro and in vivo. 
Although extrapolation of the MAA doses 
used in this study to human exposure levels 
is challenging given the paucity of data that 
exists regarding EGME and MAA levels in 
exposed humans, the anti  estrogenic effects 
of MAA we observed are consistent with the 
reproductive toxicities described for humans 
exposed to EGME (Correa et al. 1996; Welch 
et al. 1988; Welsch 2005). ERα­mediated sig­
naling is critical to reproductive function in 
both males and females, as illustrated by the 
pheno  types observed with αERKO mice. Male 
αERKO mice have reduced sperm counts, and 
both male and female αERKO mice are infer­
tile (Hewitt et al. 2005). Interestingly, these 
pheno  types are similar to those observed in 
EGME­exposed men, who have reduced sperm 
counts, and women, who exhibit decreased fer­
tility (Correa et al. 1996; Welch et al. 1988). 
In a rat model, chronic EGME exposure sup­
pressed cyclicity and prolonged diestrus, pro­
viding further in vivo evidence consistent with 
attenuation of estrogenic responsiveness (Davis 
et al. 1997). Adverse reproductive effects have 
also been reported in men and women exposed 
to the short­chain fatty acid VPA, which pos­
sesses anti  estrogenic properties similar to those 
of MAA (Isojarvi et al. 1993; O’Donovan et al. 
2002). Taken together, these observations 
suggest that MAA­mediated attenuation of 
ER signaling may play a role in the untoward 
reproductive effects observed in both males 
and females after EGME exposure.
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co r r e c t i o n
In the manuscript originally published 
online, the concentration of E2 was given as 
1 nM in Figure 1 and in the text referring 
to the figure. Also, the authors incorrectly 
noted that MAA potentiates E2 activity in 
HeLa cells in a “dose­dependent manner.” 
These have been corrected here.